Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?-Reference-Cited by-同舟云学术

Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?

Published:2008-10-07 Issue:2 Volume:15 Page:303-325
ISSN:1875-8908
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Becker Robert E.¹,Greig Nigel H.¹,Giacobini Ezio²

Affiliation:

1. Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA

2. Department of Rehabilitation and Geriatrics, University of Geneva Medical School, Geneva, Switzerland

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoscale flow cytometry‐based quantification of blood‐based extracellular vesicle biomarkers distinguishes MCI and Alzheimer's disease;Alzheimer's & Dementia;2024-07-03

2. Innovative approaches to Alzheimer's therapy: Harnessing the power of heterocycles, oxidative stress management, and nanomaterial drug delivery system;Ageing Research Reviews;2024-06

3. A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1–42 Peptide in the Brain and Leads to Alzheimer’s Disease-Relevant Cognitive Changes in a Mouse Model;Journal of Alzheimer's Disease;2024-03-05

4. Unveiling the potential of novel indol-3-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE/BACE 1 dual inhibitors: a combined in silico, synthesis and in vitro study;RSC Advances;2024

5. Visualization of Amyloid Oligomers in the Brain of Patients with Alzheimer’s Disease;ACTA HISTOCHEMICA ET CYTOCHEMICA;2023-12-28